Cargando…
A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment
A 76-year-old man was admitted to our hospital with Guillain-Barré syndrome (GBS), presenting with facial palsy, dysarthria, and dysphagia as Grade 3 immune-related adverse events (irAEs) due to pembrolizumab administration for Stage IV lung adenocarcinoma. Although prednisolone (1 mg/kg) was starte...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358493/ https://www.ncbi.nlm.nih.gov/pubmed/34344201 http://dx.doi.org/10.1177/23247096211037462 |
_version_ | 1783737352303149056 |
---|---|
author | Oguri, Tomoyo Sasada, Shinji Shimizu, Satoko Shigematsu, Risa Tsuchiya, Yumi Ishioka, Kota Takahashi, Saeko Oki, Koichi Kimura, Yoshifumi Seki, Reishi Hirose, Shigemichi Nakamura, Morio |
author_facet | Oguri, Tomoyo Sasada, Shinji Shimizu, Satoko Shigematsu, Risa Tsuchiya, Yumi Ishioka, Kota Takahashi, Saeko Oki, Koichi Kimura, Yoshifumi Seki, Reishi Hirose, Shigemichi Nakamura, Morio |
author_sort | Oguri, Tomoyo |
collection | PubMed |
description | A 76-year-old man was admitted to our hospital with Guillain-Barré syndrome (GBS), presenting with facial palsy, dysarthria, and dysphagia as Grade 3 immune-related adverse events (irAEs) due to pembrolizumab administration for Stage IV lung adenocarcinoma. Although prednisolone (1 mg/kg) was started for GBS due to the irAE, dark erythema and skin eruptions appeared on the patient’s torso. Then erosion was observed on 18% of the body surface area and skin biopsy was performed. Finally, the patient was diagnosed with Stevens-Johnson syndrome/toxic epidermal necrosis overlap. Intravenous immunoglobulin therapy was started, and the skin symptoms improved, with the erosion becoming epithelial. He died of aspiration pneumonia related to GBS, although his neurological symptoms had improved after steroid and intravenous immunoglobulin therapy. This is the first reported case of pembrolizumab-induced GBS and Stevens–Johnson syndrome/toxic epidermal necrosis overlap. It is necessary to be careful that the possibility of other severe irAEs may occur simultaneously. |
format | Online Article Text |
id | pubmed-8358493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-83584932021-08-13 A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment Oguri, Tomoyo Sasada, Shinji Shimizu, Satoko Shigematsu, Risa Tsuchiya, Yumi Ishioka, Kota Takahashi, Saeko Oki, Koichi Kimura, Yoshifumi Seki, Reishi Hirose, Shigemichi Nakamura, Morio J Investig Med High Impact Case Rep Case Report A 76-year-old man was admitted to our hospital with Guillain-Barré syndrome (GBS), presenting with facial palsy, dysarthria, and dysphagia as Grade 3 immune-related adverse events (irAEs) due to pembrolizumab administration for Stage IV lung adenocarcinoma. Although prednisolone (1 mg/kg) was started for GBS due to the irAE, dark erythema and skin eruptions appeared on the patient’s torso. Then erosion was observed on 18% of the body surface area and skin biopsy was performed. Finally, the patient was diagnosed with Stevens-Johnson syndrome/toxic epidermal necrosis overlap. Intravenous immunoglobulin therapy was started, and the skin symptoms improved, with the erosion becoming epithelial. He died of aspiration pneumonia related to GBS, although his neurological symptoms had improved after steroid and intravenous immunoglobulin therapy. This is the first reported case of pembrolizumab-induced GBS and Stevens–Johnson syndrome/toxic epidermal necrosis overlap. It is necessary to be careful that the possibility of other severe irAEs may occur simultaneously. SAGE Publications 2021-08-03 /pmc/articles/PMC8358493/ /pubmed/34344201 http://dx.doi.org/10.1177/23247096211037462 Text en © 2021 American Federation for Medical Research https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Oguri, Tomoyo Sasada, Shinji Shimizu, Satoko Shigematsu, Risa Tsuchiya, Yumi Ishioka, Kota Takahashi, Saeko Oki, Koichi Kimura, Yoshifumi Seki, Reishi Hirose, Shigemichi Nakamura, Morio A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment |
title | A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment |
title_full | A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment |
title_fullStr | A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment |
title_full_unstemmed | A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment |
title_short | A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment |
title_sort | case of guillain-barré syndrome and stevens-johnson syndrome/toxic epidermal necrosis overlap after pembrolizumab treatment |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358493/ https://www.ncbi.nlm.nih.gov/pubmed/34344201 http://dx.doi.org/10.1177/23247096211037462 |
work_keys_str_mv | AT oguritomoyo acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT sasadashinji acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT shimizusatoko acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT shigematsurisa acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT tsuchiyayumi acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT ishiokakota acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT takahashisaeko acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT okikoichi acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT kimurayoshifumi acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT sekireishi acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT hiroseshigemichi acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT nakamuramorio acaseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT oguritomoyo caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT sasadashinji caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT shimizusatoko caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT shigematsurisa caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT tsuchiyayumi caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT ishiokakota caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT takahashisaeko caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT okikoichi caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT kimurayoshifumi caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT sekireishi caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT hiroseshigemichi caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment AT nakamuramorio caseofguillainbarresyndromeandstevensjohnsonsyndrometoxicepidermalnecrosisoverlapafterpembrolizumabtreatment |